Novartis Anticipates Diovan Pricing Will Contribute To Near-Term Growth
Pending oral iron-chelating agent Exjade could be priced at a premium compared with current first-line therapy, Novartis says during its third quarter call Oct. 18.
Pending oral iron-chelating agent Exjade could be priced at a premium compared with current first-line therapy, Novartis says during its third quarter call Oct. 18.